Status:
RECRUITING
Long-term Beta-blocker Therapy After Acute Myocardial Infarction
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Kangbuk Samsung Hospital
Gyeongsang National University Hospital
Conditions:
Myocardial Infarction
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) ...
Detailed Description
β-blockers have anti-ischemic, anti-arrhythmic, and anti-adrenergic properties. In order to reduce cardiovascular mortality and morbidity, current major guidelines recommend that oral treatment of β-b...
Eligibility Criteria
Inclusion
- Subject must be at least 19 years of age.
- Subject who have been continuing β-blocker therapy for at least 1 year after acute myocardial infarction regardless of the time of diagnosis
- Subject is able to verbally confirm understandings of risks and benefits of this trial, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
Exclusion
- Subject whose left ventricle ejection fraction was less than 40% from echocardiography performed after acute myocardial infarction or who have never received echocardiography.
- Treatment history of heart failure
- Contraindication to β-blocker therapy (history of symptomatic bronchial asthma or chronic obstructive pulmonary disease, 2nd or 3rd degree AV block, cardiac pacemaker implantation, or other cases where β-blocker cannot be used under the judgment of the clinician)
- Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
- History of atrial fibrillation
- Pregnancy or breast feeding
Key Trial Info
Start Date :
May 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
2540 Patients enrolled
Trial Details
Trial ID
NCT04769362
Start Date
May 4 2021
End Date
March 31 2026
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06351